Table 2 Baseline Demographics and Characteristics
|  | Eptinezumab 100 mg | Eptinezumab 300 mg | Eptinezumab 1000 mg | Placebo |
|---|---|---|---|---|
N = 701 | N = 695 | N = 81 | N = 791 | |
Mean age, years (SD) | 39.9 (11.11) | 40.1 (10.84) | 38.6 (10.81) | 39.3 (10.96) |
Sex: Female, n (%) | 590 (84.2) | 611 (87.9) | 67 (82.7) | 686 (86.7) |
Race, n (%) | ||||
 White | 636 (90.7) | 623 (89.6) | 66 (81.5) | 677 (85.6) |
 Black / African American | 50 (7.1) | 54 (7.8) | 10 (12.3) | 84 (10.6) |
 Asian | 2 (0.3) | 3 (0.4) | 4 (4.9) | 7 (0.9) |
 American Indian / Alaska Native | 1 (0.1) | 3 (0.4) | 0 | 3 (0.4) |
 Native Hawaiian / other Pacific Islander | 1 (0.1) | 2 (0.3) | 0 | 2 (0.3) |
 Multiple races | 9 (1.3) | 8 (1.2) | 1 (1.2) | 13 (1.6) |
 Other | 2 (0.3) | 1 (0.1) | 0 | 5 (0.6) |
 Not reported | 0 | 1 (0.1) | 0 | 0 |
Mean BMI, kg/m2 | 27.6 (6.15) | 27.3 (5.91) | 27.5 (5.17) | 27.9 (6.14) |
Preventive migraine medication use, n (%)* | 52/478 (10.9) | 62/471 (13.2) | – | 49/487 (10.1) |
Cardiovascular risk factors, n (%) | ||||
 Hypertension-related | 36 (5.1) | 26 (3.7) | 1 (1.2) | 28 (3.5) |
 Hyperlipidemia-related | 48 (6.8) | 45 (6.5) | 5 (6.2) | 45 (5.7) |
 Diabetes-related | 3 (0.4) | 0 | 1 (1.2) | 5 (0.6) |
 History of ischemic CV events/procedures | 4 (0.6) | 3 (0.4) | 0 | 3 (0.4) |
 Obesity (Class 1 or 2), BMI ≥30 kg/m2 | 226 (32.2) | 197 (28.3) | 26 (32.1) | 265 (33.5) |
 Male ≥45 years | 43 (6.1) | 24 (3.5) | 4 (4.9) | 38 (4.8) |
 Female ≥55 years | 63 (9.0) | 57 (8.2) | 2 (2.5) | 49 (6.2) |
 Black or African American race | 50 (7.1) | 54 (7.8) | 10 (12.3) | 84 (10.6) |
  ≥ 1 CV risk factor | 350 (49.9) | 316 (45.5) | 41 (50.6) | 382 (48.3) |
  ≥ 2 CV risk factors | 97 (13.8) | 83 (11.9) | 7 (8.6) | 112 (14.2) |
Medical/Surgical CV history, n (%) | ||||
 Angina pectoris | 0 | 1 (0.1) | 0 | 0 |
 Aortic valve incompetence | 1 (0.1) | 0 | 0 | 0 |
 Arrhythmia | 0 | 0 | 1 (1.2) | 1 (0.1) |
 Supraventricular arrhythmia | 0 | 1 (0.1) | 0 | 0 |
 Atrioventricular block, first degree | 0 | 0 | 0 | 1 (0.1) |
 Bradycardia | 2 (0.3) | 4 (0.6) | 0 | 4 (0.5) |
 Bundle branch block, left | 1 (0.1) | 0 | 0 | 0 |
 Bundle branch block, right | 0 | 2 (0.3) | 0 | 2 (0.3) |
 Cardiomegaly | 1 (0.1) | 0 | 0 | 0 |
 Cardiomyopathy | 0 | 1 (0.1) | 0 | 0 |
 Mitral valve incompetence | 1 (0.1) | 0 | 0 | 1 (0.1) |
 Mitral valve prolapse | 1 (0.1) | 4 (0.6) | 0 | 6 (0.8) |
 Palpitations | 3 (0.4) | 2 (0.3) | 0 | 5 (0.6) |
 POTS | 1 (0.1) | 0 | 0 | 0 |
 Sinus arrhythmia | 1 (0.1) | 1 (0.1) | 0 | 0 |
 Sinus bradycardia | 0 | 0 | 0 | 2 (0.3) |
 Sinus tachycardia | 1 (0.1) | 1 (0.1) | 0 | 1 (0.1) |
 Supraventricular tachycardia | 1 (0.1) | 2 (0.3) | 0 | 1 (0.1) |
 Tachycardia | 0 | 2 (0.3) | 1 (1.2) | 5 (0.6) |
 Tricuspid valve incompetence | 1 (0.1) | 0 | 0 | 0 |
 Ventricular extrasystoles | 1 (0.1) | 0 | 0 | 1 (0.1) |
 Ventricular tachycardia | 0 | 0 | 0 | 1 (0.1) |